Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1162 participants.
Also called NCT01368081
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,162 participants
- Registry
-
NCT01368081
-
- Other papers using this trial's data
- Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01368081. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2014-06-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo (low dose)
- Intervention (Drug)
- BI 10773
- Intervention (Drug)
- Placebo (high dose)
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01368081- Content hash
da97cb7f7b1c3a2e9c4acae88720fa7437ed48fb390a518e022e990d2eecfaa2